Literature DB >> 8632892

Tob, a novel protein that interacts with p185erbB2, is associated with anti-proliferative activity.

S Matsuda1, J Kawamura-Tsuzuku, M Ohsugi, M Yoshida, M Emi, Y Nakamura, M Onda, Y Yoshida, A Nishiyama, T Yamamoto.   

Abstract

We have molecularly cloned a cDNA for a novel protein termed Tob (Transducer of ErbB-2) that interacts with the c-erbB-2 gene product p185erbB2. Nucleotide sequencing reveals that the Tob protein is a 45 kDa protein that does not contain either SH2 (Src Homology 2) or SH3 domain but is homologous to the previously characterized anti-proliferative gene product BTG-1 at its amino-terminal half. The carboxyl-terminal half of Tob is characterized by the presence of a sequence rich in proline and glutamine and shows no homology to known proteins. Like BTG-1, exogenously expressed Tob is able to suppress growth of NIH3T3 cells, but the growth suppression is hampered by the presence of kinase-active p185erbB2. By using the GST-Tob protein that contains either full length or amino-terminal half of Tob, we show that the carboxyl-terminal half of Tob is relevant to its interaction with p185erbB2. Furthermore, we could co-immunoprecipitate the Tob protein with anti-ErbB-2 antibody, and reciprocally the p185erbB2 with anti-Tob antibodies. These data suggest that p185erbB2 negatively regulates the Tob-mediated anti-proliferative pathway through its interaction with Tob, resulting possibly in growth stimulation by p185erbB2. Finally, expression of the Tob mRNA is observed in various cell types and is not correlated with expression of c-erbB-2, suggesting that other receptor-type protein-tyrosine kinases are also involved in the Tob-mediated regulation of cell growth.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8632892

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  Intercept-PCR, an improvement for elevating performance to find a new member of a certain gene family.

Authors:  S Matsuda; Y Ichigotani; T Okuda; K Miyazaki; T Yamamoto; Y Nimura; T Irimura; S Nakatsugawa; M Hamaguchi
Journal:  Mol Biotechnol       Date:  2000-09       Impact factor: 2.695

Review 2.  Quiescent T cells and HIV: an unresolved relationship.

Authors:  Dimitrios N Vatakis; Christopher C Nixon; Jerome A Zack
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

3.  The polymorphism in miR-25 attenuated the oncogenic function in gastric cancer.

Authors:  Jianping Zhou; Jiangang Zhou; Weimin Wang; Weiling Li; Lulu Wu; Gang Li; Jun Shi; Sujun Zhou
Journal:  Tumour Biol       Date:  2015-11-16

Review 4.  Metabolic regulation of T cell differentiation and function.

Authors:  Benjamin V Park; Fan Pan
Journal:  Mol Immunol       Date:  2015-08-12       Impact factor: 4.407

5.  xBtg-x regulates Wnt/beta-Catenin signaling during early Xenopus development.

Authors:  Oliver Wessely; James I Kim; Uyen Tran; Luis Fuentealba; E M De Robertis
Journal:  Dev Biol       Date:  2005-07-01       Impact factor: 3.582

6.  ANA deficiency enhances bone morphogenetic protein-induced ectopic bone formation via transcriptional events.

Authors:  Kentaro Miyai; Mitsuhiro Yoneda; Urara Hasegawa; Sayaka Toita; Yayoi Izu; Hiroaki Hemmi; Tadayoshi Hayata; Yoichi Ezura; Shuki Mizutani; Kohei Miyazono; Kazunari Akiyoshi; Tadashi Yamamoto; Masaki Noda
Journal:  J Biol Chem       Date:  2009-02-20       Impact factor: 5.157

7.  Transducer of erbB2.1 is a potential cellular target of gefitinib in lung cancer therapy.

Authors:  Ke-Kang Sun; Yang Yang; Lin Zhao; Li-Li Wang; Yang Jiao
Journal:  Oncol Lett       Date:  2012-10-15       Impact factor: 2.967

8.  Human carbon catabolite repressor protein (CCR4)-associative factor 1: cloning, expression and characterization of its interaction with the B-cell translocation protein BTG1.

Authors:  J A Bogdan; C Adams-Burton; D L Pedicord; D A Sukovich; P A Benfield; M H Corjay; J K Stoltenborg; I B Dicker
Journal:  Biochem J       Date:  1998-12-01       Impact factor: 3.857

9.  Tob1 is a constitutively expressed repressor of liver regeneration.

Authors:  Karen J Ho; Nhue L Do; Hasan H Otu; Martin J Dib; Xianghui Ren; Keiichi Enjyoji; Simon C Robson; Ernest F Terwilliger; Seth J Karp
Journal:  J Exp Med       Date:  2010-05-31       Impact factor: 14.307

10.  Retinoic acid enhances skeletal muscle progenitor formation and bypasses inhibition by bone morphogenetic protein 4 but not dominant negative beta-catenin.

Authors:  Karen A M Kennedy; Tammy Porter; Virja Mehta; Scott D Ryan; Feodor Price; Vian Peshdary; Christina Karamboulas; Josée Savage; Thomas A Drysdale; Shun-Cheng Li; Steffany A L Bennett; Ilona S Skerjanc
Journal:  BMC Biol       Date:  2009-10-08       Impact factor: 7.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.